Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer

MLA

Scott M. Lippman, et al. “Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer.” Clinical Cancer Research, vol. 14, Jan. 2008, pp. 224–29. EBSCOhost, https://doi.org/10.1158/1078-0432.ccr-07-0733.

APA

Scott M. Lippman, Anita L. Sabichi, Mary Wargo, Seth P. Lerner, Howard L. Parnes, H. Barton Grossman, Archie Bleyer, Dean E. Brenner, David F. Penson, John L. Clifford, Nancy P. Caraway, Ashish M. Kamat, Louis L. Pisters, Ruth L. Katz, Surena F. Matin, Daniel W. Lin, E. Neely Atkinson, William H. Sanders, George P. Hemstreet, & Colin P.N. Dinney. (2008). Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 14, 224–229. https://doi.org/10.1158/1078-0432.ccr-07-0733

Chicago

Scott M. Lippman, Anita L. Sabichi, Mary Wargo, Seth P. Lerner, Howard L. Parnes, H. Barton Grossman, Archie Bleyer, et al. 2008. “Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer.” Clinical Cancer Research 14 (January): 224–29. doi:10.1158/1078-0432.ccr-07-0733.